c12蛋白芯片-2021.10.11

多肿瘤标志物C12蛋白芯片对晚期胃肠癌的诊断有一定价值 认领
The clinical significance of C12 multi-tumor markers protein chip diagnostic system in the diagnosis of gastrointestinal cancer
收藏分享导出
摘要目的:探讨多肿瘤标志物C12蛋白芯片检测系统在胃肠癌的诊断价值。方法:分析总结329例胃肠癌初治患者C12芯片的检测结果,寻找出与胃肠癌相关性最强的肿瘤标志物,计算各种肿瘤标志物组合方式对提高诊断率的贡献。结果:C12系统对本组329例胃肠癌患者的总体诊断率为39.21%,Ⅰ、Ⅱ、Ⅲ、Ⅳ期患者的诊断率分别为13.73%、33.33%、38.30%、58.03%。肿瘤标志物阳性率在各临床分期中的整体差异具有统计学显著性(P<0.01),Ⅰ期与Ⅲ期、Ⅰ期与Ⅳ期、Ⅱ期与Ⅳ期差异具有统计学显著性(P<0.01),其余分期相比没有统计学显著性(P>0.05)。C12系统中阳性率最高的三种TM是CEA、CA242和CA19-9,阳性率分别为27.36%、19.76%和19.45%,并且与肿瘤的分期相关。结论:C12检测系统对晚期胃肠癌的诊断有一定的价值,但对早期的敏感性不高,临床迫切需要微型高效的胃肠癌检测系统。
Objective：To assess the value of tumor markers（TMs） protein chip diagnostic system C12 in the diagnosis of gastrointestinal cancer（GIC）. Methods ：The sera of 329 pathologically-confirmed GIC patients were detected by the C 12 protein biochip system. The most relevant TMs and the contribution of various combinations of TMs to the improvement of diagnosis were determined. Results：The diagnostic rates of C12 biochip system in 329 GIC patients were 13.73%,33.33%,38.30%,58.03% for stages Ⅰ , Ⅱ, Ⅲ and Ⅳ patients, respectively,and the overall diagnostic rate was 39.21%. There were statistically significant difference （P 〈 0.01） among all clinical stages （contingency table chi-square test）, stage Ⅰ versus stage Ⅲ ,stage Ⅰ versus stage IV ,and stage Ⅱ versus stage IV. The other comparisons didn＇t have statistical significance （P 〉 0.05）. Among all the 12 TMs,the top three positive rates of 27.36%, 19.76% and 19.45% were obtained from CEA, CA242 and CA 19-9, respectively,which were correlated with the stage of GIC. Conclusion：The C 12 biochip diagnostic system has some value in the diagnosis of advanced GIC, but its sensitivity for early stage is poor. The miniature and effective diagnostic system is needed in clinic urgently.
作者杨雪琴 陈创 候晋轩 杨国梁 李雁
机构地区荆楚理工学院医学院 武汉大学中南医院肿瘤生物学行为湖北省重点实验室
出处《南京医科大学学报：自然科学版》 CAS CSCD 北大核心 2008年第10期1285-1289,共5页
基金荆门市科技计划项目(08S12) 教育部新世纪优秀人才支持计划(NCET-04-0669) 全国优秀博士学位论文作者专项资金资助项目(200464) 武汉市创新研究课题资助(20066002054)
关键词胃癌 结直肠癌 肿瘤标志物 临床分期 蛋白芯片
gastric cancer colorectal cancer tumor marker clinical staging protein biochip
分类号R730.4 [医药卫生—肿瘤]
引文网络 相关文献
节点文献
二级参考文献72
参考文献15
共引文献728
同被引文献0
引证文献0
二级引证文献0
参考文献15
1Parkin DM,Bray F,Pisani P. Global cancer statistics, 2002[J]. CA Cancer J Clin,2005,55(2):74-108 被引量：1
2孙秀娣,牧人,周有尚,戴旭东,张思维,皇甫小梅,孙杰,李连弟,鲁凤珠,乔友林.中国胃癌死亡率20年变化情况分析及其发展趋势预测[J].中华肿瘤杂志,2004,26(1):4-9. 被引量：649
3郑树.结直肠癌的预防[J].中华肿瘤防治杂志,2006,13(1):1-2. 被引量：33
4Ludwig JA,Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection [J]. Nat Rev Cancer, 2005,5( 11 ) : 845-856 被引量：1
5Sun Z,Fu X,Zhang L,et al. A protein chip system for parallel analysis of muhi-tumor markers and its application in cancer detection [J]. Anticancer Res,2004,24 (2C) : 1159-1165 被引量：1
6于大洋.蛋白芯片检测系统对不同肿瘤检测组合评价的探讨[J].中国热带医学,2005,5(3):414-416. 被引量：9
7董学君,郑专,陈建军,池静,傅燕萍,王伟.蛋白芯片多肿瘤标志物中胃癌相关指标的筛选[J].中国实验诊断学,2005,9(1):88-90. 被引量：5
8梁茱,王海枫,吴爱祝,符生苗.12项肿瘤标志物蛋白芯片检测消化系统肿瘤的临床意义[J].中国热带医学,2005,5(3):407-409. 被引量：12
9牟江洪,李增鹏,王东,马瑜,肖华亮,张沁宏.大肠癌多种肿瘤标志物蛋白芯片联合检测及其在诊断中的意义[J].消化外科,2005,4(4):268-270. 被引量：19
10郑辉,吴赟,孔建新,马筱玲.多肿瘤标志物蛋白芯片检测系统的临床应用分析[J].安徽医药,2006,10(4):273-275. 被引量：13
12>